Translating metastasis-related biomarkers to the clinic - Progress and pitfalls

Nature Reviews Clinical Oncology

Volumn 10, Issue 3, 2013, Pages 169-179

  Bidard, François Clément ^a   Pierga, Jean Yves ^a   Soria, Jean Charles ^b   Thiery, Jean Paul ^c,d,e  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c AGENCY FOR SCIENCE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; PROGESTERONE RECEPTOR; TRANSCRIPTOME; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS; GENETIC HETEROGENEITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAXIMUM TOLERATED DOSE; MEDICAL PRACTICE; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM MICROMETASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; ORGAN SPECIFICITY; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTOME; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84874651590     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.4     Document Type: Review

References (151)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Kishimoto, H. et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat. Med. 12, 1213-1219 (2006).
3. Beerling, E., Ritsma, L., Vrisekoop, N., Derksen, P. W. & van Rheenen, J. Intravital microscopy: new insights into metastasis of tumors. J. Cell Sci. 124, 299-310 (2011).
4. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
5. Denoix, P. Enquete permanente dans les centres anticancereux. Bull. Inst. Natl Hyg. 1, 12-17 (1946).
6. th edition. Acta Chir. Belg. 111, 389-392 (2011).
7. th edn (Wiley Blackwell, Hoboken, 2009).
8. Mego, M., Mani, S. A. & Cristofanilli, M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 7, 693-701 (2010).
9. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
10. Sethi, N. & Kang, Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat. Rev. Cancer 11, 735-748 (2011).
11. Kleer, C. G. et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 12, 4485-4490 (2006).
12. Wang, W. et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br. J. Cancer 90, 2349-2355 (2004).
13. Kondo, T. et al. Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology 71, 19-25 (2004).
14. Kamai, T. et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9, 2632-2641 (2003).
15. Kleer, C. G. et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am. J. Pathol. 160, 579-584 (2002).
16. Hu, G. et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15, 9-20 (2009).
17. Li, J. et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin. Cancer Res. 14, 3319-3326 (2008).
18. Prat, A., Ellis, M. J. & Perou, C. M. Practical implications of gene-expression-based assays for breast oncologists. Nat. Rev. Clin. Oncol. 9, 48-57 (2012).
19. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
20. Foekens, J. A. et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
21. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
22. Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
23. Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007).
24. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
25. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
26. Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
27. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
28. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010).
29. Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273-4278 (2011).
30. Bogaerts, J. et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol. 3, 540-551 (2006).
31. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
32. Rutgers, E. et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur. J. Cancer 47, 2742-2749 (2011).
33. Mook, S. et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur. J. Cancer 45, 1201-1208 (2009).
34. Bernards, R. & Weinberg, R. A. A progression puzzle. Nature 418, 823 (2002).
35. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
36. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
37. Millar, E. K. et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J. Clin. Oncol. 27, 4701-4708 (2009).
38. Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108-3114 (2008).
39. Desmedt, C., Ruíz-García, E. & André, F. Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur. J. Cancer 44, 2714-2720 (2008).
40. Ng, C., Weigelt, B., Grigoriadis, A. & Reis-Filho, J. S. Prognostic signatures in breast cancer: correlation does not imply causation. Breast Cancer Res. 14, 313 (2012).
41. Michiels, S., Koscielny, S. & Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488-492 (2005).
42. Ein-Dor, L., Zuk, O. & Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103, 5923-5928 (2006).
43. Weigelt, B. et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11, 339-349 (2010).
44. Mackay, A. et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J. Natl Cancer Inst. 103, 662-673 (2011).
45. Vignot, S., Besse, B., André, F., Spano, J. P. & Soria, J. C. Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. Crit. Rev. Oncol. Hematol. (2012).
46. Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587-592 (2012).
47. Nelson, P. S. Predicting prostate cancer behavior using transcript profiles. J. Urol. 172, S28-S32 (2004).
48. Markert, E. K., Mizuno, H., Vazquez, A. & Levine, A. J. Molecular classification of prostate cancer using curated expression signatures. Proc. Natl Acad. Sci. USA 108, 21276-21281 (2011).
49. Sørensen, K. D. & Ørntoft, T. F. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev. Mol. Diagn. 10, 49-64 (2010).
50. Agulló-Ortuño, M. T., López-Ríos, F. & Paz-Ares, L. Lung cancer genomic signatures. J. Thorac. Oncol. 5, 1673-1691 (2010).
51. Boutros, P. C. et al. Prognostic gene signatures for non-small-cell lung cancer. Proc. Natl Acad. Sci. USA 106, 2824-2828 (2009).
52. Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 29, 17-24 (2011).
53. Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611-4619 (2011).
54. Zhang, Y. et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res. 69, 3795-3801 (2009).
55. Berns, E. M. & Bowtell, D. D. The changing view of high-grade serous ovarian cancer. Cancer Res. 72, 2701-2704 (2012).
56. Roessler, S. et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142, 957-966.e912 (2012).
57. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
58. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
59. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
60. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
61. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
62. Yu, Y. Y. & Zhu, Z. G. Significance of biological resource collection and tumor tissue bank creation. World J. Gastrointest. Oncol. 2, 5-8 (2010).
63. Reshmi, G., Sona, C. & Pillai, M. R. Comprehensive patterns in microRNA regulation of transcription factors during tumor metastasis. J. Cell. Biochem. 112, 2210-2217 (2011).
64. Lovat, F., Valeri, N. & Croce, C. M. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 38, 724-733 (2011).
65. Hurst, D. R., Edmonds, M. D. & Welch, D. R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 69, 7495-7498 (2009).
66. Nair, V. S., Maeda, L. S. & Ioannidis, J. P. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J. Natl Cancer Inst. 104, 528-540 (2012).
67. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889).
68. Smid, M. et al. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24, 2261-2267 (2006).
69. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
70. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891 (2012).
71. Zhang, L. et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 18, 5701-5710 (2012).
72. Muller, V., Alix-Panabieres, C. & Pantel, K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur. J. Cancer 46, 1189-1197 (2010).
73. Vincent-Salomon, A., Bidard, F. C. & Pierga, J. Y. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J. Clin. Pathol. 6, 570-576 (2008).
74. Joosse, S. A. et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 18, 993-1003 (2012).
75. Müller, V. et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 14, R118 (2012).
76. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
77. Janni, W. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin. Cancer Res. 17, 2967-2976 (2011).
78. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
79. Stoecklein, N. H. et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13, 441-453 (2008).
80. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351 (2009).
81. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007).
82. Uhr, J. W. & Pantel, K. Controversies in clinical cancer dormancy. Proc. Natl Acad. Sci. USA 108, 12396-12400 (2011).
83. Bidard, F. C. et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann. Oncol. 19, 496-500 (2008).
84. Riethdorf, S., Wikman, H. & Pantel, K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 123, 1991-2006 (2008).
85. Rahbari, N. N. et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138, 1714-1726 (2010).
86. Lucci, A. et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 13, 688-695 (2012).
87. Miller, M. C., Doyle, G. V. & Terstappen, L. W. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 617421 (2010).
88. Pierga, J. Y. et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 23, 618-624 (2012).
89. Rack, B. et al. Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial [abstract]. J. Clin. Oncol. 26 (Suppl.), a503 (2008).
90. Molloy, T. J. et al. The prognostic significance of tumor cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 13, R61 (2011).
91. th edn (eds Edge, S. B. et al.) 347-376 (Springer, New York, 2009).
92. Coumans, F. A., Ligthart, S. T., Uhr, J. W. & Terstappen, L. W. Challenges in the enumeration and phenotyping of CTC. Clin. Cancer Res. 18, 5711-5718 (2012).
93. Saliba, A. E. et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc. Natl Acad. Sci. USA 107, 14524-14529 (2010).
94. Tan, S. J. et al. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens. Bioelectron. 26, 1701-1705 (2010).
95. Autebert, J. et al. Microfluidic: an innovative tool for efficient cell sorting. Methods 57, 297-307 (2012).
96. Higgins, M. J. et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18, 3462-3469 (2012).
97. Madic, J. et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin. Cancer Res. 18, 3934-3941 (2012).
98. Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
99. Alix-Panabieres, C., Schwarzenbach, H. & Pantel, K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63, 199-215 (2012).
100. Schwarzenbach, H. et al. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin. Cancer Res. 18, 5719-5730 (2012).
101. Weigelt, B. et al. No common denominator for breast cancer lymph node metastasis. Br. J. Cancer 93, 924-932 (2005).
102. Ellsworth, R. E. et al. Differential gene expression in primary breast tumors associated with lymph node metastasis. Int. J. Breast Cancer 2011, 142763 (2011).
103. Naume, B. et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 1, 160-171 (2007).
104. Woelfle, U. et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 63, 5679-5684 (2003).
105. Reyal, F. et al. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann. Oncol. 22, 1458-1459 (2011).
106. Meng, S. et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101, 9393-9398 (2004).
107. Powell, A. A. et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 7, e33788 (2012).
108. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737-7742 (2003).
109. Ligthart, S. T. et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non metastatic breast cancer. Ann. Oncol. 10.1093/annonc/mds625 (2012).
110. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
111. International Cancer Genome Consortium. ICGC Cancer Genome Projects [online], http://www.icgc.org/(2012).
112. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
113. Gray, J. & Druker, B. Genomics: The breast cancer landscape. Nature 486, 328-329 (2012).
114. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
115. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
116. Hartmaier, R. J., Priedigkeit, N. & Lee, A. V. Who's driving anyway? Herculean efforts to identify the drivers of breast cancer. Breast Cancer Res. 14, 323 (2012).
117. Pushkarev, D., Neff, N. F. & Quake, S. R. Singlemolecule sequencing of an individual human genome. Nat. Biotechnol. 27, 847-852 (2009).
118. Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M. & Gelmon, K. A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11, 174-183 (2010).
119. Thiolloy, S. & Rinker-Schaeffer, C. W. Thinking outside the box: using metastasis suppressors as molecular tools. Semin. Cancer Biol. 21, 89-98 (2011).
120. Steeg, P. S. Perspectives on classic article: metastasis suppressor genes. J. Natl Cancer Inst. 96, E4 (2004).
121. Shoushtari, A. N., Szmulewitz, R. Z. & Rinker-Schaeffer, C. W. Metastasis-suppressor genes in clinical practice: lost in translation? Nat. Rev. Clin. Oncol. 8, 333-342 (2011).
122. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416-422 (2005).
123. Abdi, H. The Bonferonni and Šidák Corrections for Multiple Comparisons in Encyclopedia of Measurement and Statistics (ed. Salkind, N. J.) 103-107 (Thousand Oaks, CA, Sage, 2007).
124. André, F. et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8, 171-176 (2011).
125. Hayes, D. F. et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88, 1456-1466 (1996).
126. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446-1452 (2009).
127. Hsieh, S. M., Look, M. P., Sieuwerts, A. M., Foekens, J. A. & Hunter, K. W. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res. 11, R75 (2009).
128. Esserman, L. J. et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res. Treat. 129, 607-616 (2011).
129. Saghatchian, M. et al. Characterization of breast cancer distant metastasis based on outcome over time using a gene expression profiling approach and identification of pathway activities of late relapse. 71 (Suppl. 3), Cancer Res. S1-S6 (2011).
130. Bidard, F. C. et al. Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin. Exp. Metastasis 25, 871-875 (2008).
131. Paez, D. et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin. Cancer Res. 18, 645-653 (2012).
132. Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207-3214 (2007).
133. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
134. Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122 (2010).
135. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012).
136. Ocaña, A., Pandiella, A., Siu, L. L. & Tannock, I. F. Preclinical development of molecular-targeted agents for cancer. Nat. Rev. Clin. Oncol. 8, 200-209 (2010).
137. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109-3116 (2009).
138. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
139. Hayes, D. F., Trock, B. & Harris, A. L. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res. Treat. 52, 305-319 (1998).
140. Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
141. de Bono, J. S. et al. Potential applications for circulating tumor cells expressing the insulinlike growth factor-I receptor. Clin. Cancer Res. 13, 3611-3616 (2007).
142. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
143. Steeg, P. S. Perspective: The right trials. Nature 485, S58-59 (2012).
144. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
145. Coleman, R., Gnant, M., Morgan, G. & Clezardin, P. Effects of bone-targeted agents on cancer progression and mortality. J. Natl Cancer Inst. 104, 1059-1067 (2012).
146. Bidard, F. C. et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. http://dx.doi.org/10.1007/s10555-012-9398-0.
147. Tournoux-Facon, C., De Rycke, Y. & Tubert-Bitter, P. How a new stratified adaptive phase II design could improve targeting population. Stat. Med. 30, 1555-1562 (2011).
148. Glimelius, B. & Lahn, M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann. Oncol. 22, 1717-1725 (2011).
149. Alonso, D. F., Ripoll, G. V., Garona, J., Iannucci, N. B. & Gomez, D. E. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr. Pharm. Biotechnol. 12, 1974-1980 (2011).
150. Pivot, X. et al. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC) [abstract]. Ann. Oncol. 23, LBA11 (2012).
151. Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).